Biomaterial

In biomedical engineering, a biomaterial is a material selected or designed to interact with a biological system for a medical purpose. Its defining feature is this intended interaction, rather than whether it originated in an organism. A synthetic polymer, a metal or a ceramic can therefore be a biomaterial; natural collagen can also be processed for such a use. The biomedical meaning should be distinguished from the broader use of “bio” to mean material obtained from biomass.^[ref]

A biomaterial has both a material function and a biological environment. A load-bearing component must transmit forces without unacceptable deformation, but its surface also contacts fluid, proteins and biological cells. Biocompatibility consequently concerns an appropriate host response for a particular application; it is not a universal label that guarantees identical behavior at every site or for every exposure duration.^[ref]

An illuminating historical example is the 1971 work of L. L. Hench and colleagues on a bone-bonding glass-ceramic. They compared laboratory measurements of glass-ceramic solubility and interfacial hydroxyapatite crystallization with histology and ultrastructure observations around implants in rat femurs. The important question was how the material–bone interface developed, rather than merely whether the bulk ceramic was strong.^[ref]

To separate bulk behavior from an interface effect in a model experiment, one could compare specimens with identical dimensions and bulk Young's modulus but different surface treatments, while holding the cell culture conditions fixed. Measure both the mechanical response and cell adhesion, instead of substituting one for the other. Conversely, changing specimen thickness while retaining the same surface can change bending resistance without changing the nominal surface chemistry. These controlled comparisons show why evaluating a biomaterial requires specifying the material, its geometry, its interface and the biological setting together.

A bioactive glass is a glass designed to elicit a useful biological response at its interface, notably bonding with bone for some compositions and uses. It is a class of biomaterials, not a claim that every glass has the same response. Related glass-ceramics contain crystalline phases and should be distinguished from wholly glassy materials.

A motivating early experiment compared glass-ceramic solubility and interfacial hydroxyapatite crystallization with observations around implants in rat femurs. Larry L. Hench and colleagues examined histology and ultrastructure as well as laboratory interfacial changes. The question was how bonding developed at the material–bone interface, beyond the bulk material's mechanical strength.^[ref]

Contact with fluid can change the material's surface and release dissolved constituents. Geometry therefore matters alongside composition. For an original monodisperse spherical-powder model, radius $r$ and density $\rho$ give surface area per massAt stipulated $\rho =2500\mathrm{kg}{\mathrm{m}}^{-3}$ and $r=10\mu \mathrm{m}$, this is $120{\mathrm{m}}^2\mathrm{k}{\mathrm{g}}^{-1}$, or $0.12{\mathrm{m}}^2{\mathrm{g}}^{-1}$. Increasing radius to $100\mu \mathrm{m}$ reduces that area per mass tenfold. The example neglects pores and aggregation and is not a particular product's specification.

If initial release flux per unit area were equal in two such powders, their initial release rates per mass would differ by the same factor. Actual flux can change with solution composition and surface evolution; a biological response need not scale linearly with geometric area. Comparisons should therefore specify particle dimensions, exposed area, fluid conditions and time. Surface-layer formation, cytotoxicity, mechanical behavior and tissue bonding remain distinct observations rather than interchangeable proof of suitability.

Biocompatibility is the ability of a biomaterial to function with an appropriate response from the living system in a specified application. It relates the material, its intended function and its biological environment. It is therefore more informative to ask whether a particular finished component is compatible with a particular contact site and duration than to call a substance universally “biocompatible.”^[ref]

Consider the same nominal polymer used as a short-lived skin-contacting film or as part of a long-lived component contacting blood. Its chemistry alone does not specify the biological exposure. Surface treatment, processing residues, final preparation and the length and type of contact can change the relevant response. The FDA’s primary resource emphasizes the final finished device and explicitly identifies contact type, duration and component interactions as assessment variables.^[ref]

A cytotoxicity experiment addresses one part of this question by examining adverse effects on biological cells. In a simple illustrative cell culture comparison, suppose a sample-exposed culture has 900 viable cells and a matched control has 1000 at the same observation time. The relative viable-cell count is $900/1000=0.90$. That ratio is an observation under the chosen conditions, not a complete compatibility verdict: growth rate, exposure preparation, measurement method and repeatability affect its interpretation. A control can distinguish a material-associated effect from an effect of the culture medium or preparation procedure.

Functional compatibility also need not mean that nothing happens at the interface. Some biomaterials are designed to bond to bone, so the desired response differs from that of a material intended merely to remain separated from surrounding tissue. Evidence about cell viability, local tissue organization and the component’s mechanical function answers different questions. A useful experimental account states which response was measured, the biological setting and exposure history, and the uncertainty in the comparison.